NEW YORK – Interpace Diagnostics said today that its subsidiary Interpace BioPharma has partnered with Beijing, China-based Genecast Biotechnology to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies.
As part of the collaboration, Parsippany, New Jersey-based Interpace will perform services worldwide except in China, where Genecast will provide services.
"This collaboration is in line with our business strategy of driving sustainable, long-term growth and profitability by leveraging our unique capabilities," Michael McCartney, Interpace Biopharma chief commercial officer, said in a statement.
Financial details of the agreement were not disclosed.
"This partnership with Interpace will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally and is in line with our strategy of helping pharmaceutical and biotech companies to accelerate their biomarker-driven drug development and drive precision medicine forward," Genecast CEO and Cofounder Du Bo said in a statement.